Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 208Breast 53Gastrointestinal 44Genitourinary 41Thoracic 28Sarcoma 23Dermatologic 17CNS 15Lymphoid 11Other solid neoplasm 9Other hematologic neoplasm 8Plasma cell 6Head & Neck 6Myeloid 4Endocrine 4Other 1NET 1Classical hematology 1

Conditions

Neuroendocrine Tumors 20Carcinoma, Neuroendocrine 6von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Melanoma 2Breast Neoplasms 2Vipoma 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 1fludarabine 1aldesleukin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ovarian Neoplasms × NET × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡